


**Product Name** : JNJ-61803534  
**Cat. No.** : PC-72400  
**CAS No.** : 1917306-14-9  
**Molecular Formula** : C<sub>23</sub>H<sub>23</sub>Cl<sub>2</sub>F<sub>6</sub>N<sub>3</sub>O<sub>4</sub>S  
**Molecular Weight** : 622.404  
**Target** : ROR  
**Solubility** : 10 mM in DMSO



### Biological Activity

JNJ-61803534 (JNJ 61803534) is a novel, selective and potent **ROR $\gamma$ t** inverse agonist, inhibits ROR $\gamma$ t-driven transcription with IC<sub>50</sub> of 9.6 nM in 1-hybrid reporter assays.

JNJ-61803534 demonstrated high selectivity for ROR $\gamma$ t over ROR $\alpha$  and ROR $\beta$  (IC<sub>50</sub>>2  $\mu$ M), as well as against 18 human nuclear receptors and a panel of 52 receptors, ion channels and transporters, 28 GPCRs.

JNJ-61803534 dose-dependently suppressed production of IL-17A, IL-17F and IL-22 with IC<sub>50</sub> values of 19nM, 22 nM and 27 nM, respectively, in human CD4<sup>+</sup> T cells under Th17 differentiation, does not impair human nTreg suppressive function.

JNJ-61803534 specifically blocked ROR $\gamma$ t-dependent pathways in cellular assays and significantly reduced inflammation in preclinical models.

### References

Xiaohua Xue, et al. **Sci Rep.** 2021 May 26;11(1):11066.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com